Aberdeen Group’s Genmab GMAB Stock Holding History

Aberdeen Group’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-49,797	Closed	-$1.49M	–	958
2024 Q1	$1.49M	Buy	+49,797	New	+$1.46M	﹤0.01%	800

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aberdeen Group's GMAB Position: Q2 2024 in Review

Aberdeen Group sold out of Genmab (GMAB) in Q2 2024, closing a stake of 49,797 shares — an estimated $1.49M sold.

Aberdeen Group first reported a position in GMAB in Q1 2024 and held it in 1 quarter. The position peaked at $1.49M in Q1 2024. 219 funds tracked by Wall St. Rank hold GMAB as of Q2 2024.

Aberdeen Group reported no remaining Genmab position as of Q2 2024 after selling out during the quarter.
Aberdeen Group sold 49,797 Genmab shares in Q2 2024, an estimated $1.49M.
Aberdeen Group first reported a position in Genmab in Q1 2024 and held it in 1 quarter.
Aberdeen Group's Genmab position peaked at $1.49M in Q1 2024.
219 funds tracked by Wall St. Rank held Genmab as of Q2 2024.

Based on Aberdeen Group's 13F filing for Q2 2024, filed 9 Aug 2024.